Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629966 · ClinicalTrials.gov registry record · Phase 3
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
NCT01629966: Completed Phase 3 study, sponsored by Forest Laboratories.
NCT01629966 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 680 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01629966, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
Primary Outcome
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.
Interventions
- DRUG Placebo
- DRUG Vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2012-06-30 |
| Est. Completion | 2014-03-31 |
| Phase | Phase 3 |
What the finished NCT01629966 record still lists
NCT01629966 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01629966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01629966 about?
NCT01629966 is a clinical study titled "Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder". The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
What is the current status of trial NCT01629966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2012-06-30. Estimated completion is 2014-03-31.
What interventions are being tested in trial NCT01629966?
The interventions under investigation include: Placebo (DRUG), Vilazodone (DRUG).
Who is sponsoring clinical trial NCT01629966?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01629966's enrollment target sits among peer trials
680 532nd of 2000 higher than 1,465 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI